18/05/2026 FDA approved IMMGOLIS™ and IMMGOLIS INTRI™ biosimilars for RA and UC FDA approved IMMGOLIS™ and IMMGOLIS INTRI™ biosimilars for RA and UC (Ref) Accord Biopharma announced that the US FDA had approved IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) biosimilar for rheumatoid arthritis (RA) and ulcerative colitis (UC). IMMGOLIS™ (golimumab-sldi), a biosimilar to Simponi® (golimumab), was approved for the treatment of adult patients with moderately to s